# Cethromycin pharmacokinetics and pharmacodynamics for single dose cure of Plasmodium berghei liver stages

**Authors:** Grace Kennedy, Rachel M. West, Kristin Poti, Bryce Bobb, Matthew M. Ippolito, Mark A. Marzinke, Nikola Kaludov, David J. Sullivan

PMC · DOI: 10.1128/aac.00215-25 · Antimicrobial Agents and Chemotherapy · 2025-06-17

## TL;DR

Cethromycin shows strong antiprotozoal activity against malaria liver stages in mice, with potential for rapid clinical development.

## Contribution

Demonstrates that a single dose of cethromycin can cure Plasmodium berghei liver-stage infection in mice.

## Key findings

- Cethromycin achieves high liver concentrations in mice, with sustained levels above 10 μM for 20 hours.
- A single oral dose of 60 mg/kg cethromycin completely cured P. berghei liver-stage infection in mice.
- Cethromycin showed no effect on Plasmodium falciparum gametocyte transmission in mosquito feeding assays.

## Abstract

Cethromycin combines a quinoline nucleus and a macrolide for broad-spectrum antibacterial and antiprotozoan activity. Here, we characterized the murine pharmacokinetics and Plasmodium berghei lifecycle stage pharmacodynamics for the cethromycin base. Liver pharmacokinetic studies in mice show peak mM drug concentrations in the liver with 20 hour sustained levels above 10 μM. Peak concentrations in the liver were double the lung and about 440 times that of plasma. Immunofluorescence imaging of in vitro cethromycin-treated infected hepatocytes shows complete ablation of the apicoplast. We observed complete cure of P. berghei liver-stage infection by a single oral dose of 60 mg/kg in mice, which is equivalent to the 5 mg/kg human dose of 300 mg a day used in bacterial pneumonia studies. Cethromycin at 60 mg/kg daily for 7 days was curative in the high parasitemic P. berghei mouse model. Both mosquito membrane feeding of Plasmodium falciparum gametocytes incubated with 20 μM cethromycin and oral dosing in mice demonstrated no decrease in oocyst numbers. Cethromycin has been evaluated for efficacy against bacterial pneumonia in more than 5,000 patients with good safety profiles. Cethromycin has potential for rapid clinical development for casual malaria prophylaxis and possibly radical cure of dormant liver Plasmodium vivax.

## Linked entities

- **Chemicals:** cethromycin (PubChem CID 156417)
- **Diseases:** malaria (MONDO:0005136), bacterial pneumonia (MONDO:0004652)
- **Species:** Plasmodium berghei (taxon 5821), Plasmodium falciparum (taxon 5833), Mus musculus (taxon 10090)

## Full-text entities

- **Diseases:** bacterial pneumonia (MESH:D018410), infection (MESH:D007239), malaria (MESH:D008288)
- **Chemicals:** macrolide (MESH:D018942), Cethromycin (MESH:C405499), quinoline (MESH:C037219)
- **Species:** Plasmodium vivax (malaria parasite P. vivax, species) [taxon 5855], Homo sapiens (human, species) [taxon 9606], Plasmodium berghei (species) [taxon 5821], Mus musculus (house mouse, species) [taxon 10090], Plasmodium falciparum (malaria parasite P. falciparum, species) [taxon 5833]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12326986/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12326986/full.md

## References

43 references — full list in the complete paper: https://tomesphere.com/paper/PMC12326986/full.md

---
Source: https://tomesphere.com/paper/PMC12326986